Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP19A1 | P11511 | 13/20 | 0.51 |
| ▸ | FNTA | P49354 | 1/20 | 0.49 |
| ▸ | FNTB | P49356 | 1/20 | 0.49 |
| ▸ | CYP17A1 | P05093 | 3/20 | 0.49 |
| ▸ | MEN1 | O00255 | 1/20 | 0.48 |
| ▸ | NR1I2 | O75469 | 1/20 | 0.48 |
| ▸ | USP2 | O75604 | 1/20 | 0.48 |
| ▸ | ABCB11 | O95342 | 1/20 | 0.48 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.48 |
| ▸ | PLA2G1B | P04054 | 1/20 | 0.48 |
| ▸ | TP53 | P04637 | 1/20 | 0.48 |
| ▸ | PGR | P06401 | 1/20 | 0.48 |
| ▸ | HSP90AA1 | P07900 | 1/20 | 0.48 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.48 |
| ▸ | MAPT | P10636 | 1/20 | 0.48 |
| ▸ | IDO1 | P14902 | 1/20 | 0.48 |
| ▸ | HPGD | P15428 | 1/20 | 0.48 |
| ▸ | MAOA | P21397 | 1/20 | 0.48 |
| ▸ | CNR1 | P21554 | 1/20 | 0.48 |
| ▸ | HTR2A | P28223 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Oxalic Acid SCHEMBL7668360 | 0.95 | FNTA (0.48) | CYP19A1FNTAFNTBCYP17A1MEN1 | |
| Oxalic Acid SCHEMBL7668363 | 0.95 | FNTA (0.48) | CYP19A1FNTAFNTBCYP17A1MEN1 | |
| SCHEMBL7092407 | 0.77 | FNTA (0.56) | CYP19A1FNTAFNTBCYP17A1MEN1 | |
| SCHEMBL6305490 | 0.76 | FNTA (0.81) | CYP19A1FNTAFNTBCYP17A1MEN1 | |
| SCHEMBL10642922 | 0.71 | CYP19A1 (1.00) | CYP19A1CYP17A1MEN1NR1I2USP2 | |
| SCHEMBL3525316 | 0.71 | FNTA (0.47) | FNTAFNTBCYP3A4MAPT | |
| SCHEMBL6867606 | 0.71 | FNTA (0.67) | CYP19A1FNTAFNTBCYP17A1MEN1 | |
| SCHEMBL6309676 | 0.69 | CYP19A1 (0.44) | CYP19A1FNTAFNTBCYP17A1MEN1 | |
| SCHEMBL6866443 | 0.69 | FNTA (0.88) | CYP19A1FNTAFNTBCYP17A1MEN1 | |
| SCHEMBL11349905 | 0.69 | CYP17A1 (1.00) | CYP19A1CYP17A1MEN1NR1I2USP2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 96 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| JP-4725940-B2 | — | — | 2011-07-13 | — | — | JP | claimed |
| EP-2155197-A2 | TREATMENT OF LYSOSOMAL STORAGE DISEASES | Link Medicine Corporation (US) | 2010-02-24 | — | — | EP | claimed |
| EP-1809265-A4 | METHODS FOR THE TREATMENT OF SYNUCLEINOPATHIES | BRIGHAM & WOMENS HOSPITAL (US) | 2009-06-17 | — | — | EP | claimed |
| WO-2008112525-A2 | TREATMENT OF LYSOSOMAL STORAGE DISEASES | LINK MEDICINE CORPORATION (US) | 2008-09-18 | — | — | WO | claimed |
| EP-1809265-A2 | METHODS FOR THE TREATMENT OF SYNUCLEINOPATHIES | THE BRIGHAM AND WOMEN'S HOSPITAL, INC. (US) | 2007-07-25 | — | — | EP | claimed |
| WO-2005089504-A2 | METHODS FOR THE TREATMENT OF SYNUCLEINOPATHIES | THE BRIGHAM AND WOMEN'S HOSPITAL, INC. (US) | 2005-09-29 | — | — | WO | claimed |
| US-20030119843-A1 | 1,2-annelated quinoline derivatives | JANSSEN PHARMACEUTICA, N.V. | 2003-06-26 | — | — | US | claimed |
| EP-1140935-B1 | 1,2-ANNELATED QUINOLINE DERIVATIVES | JANSSEN PHARMACEUTICA NV (BE) | 2003-05-14 | — | — | EP | claimed |
| US-6458800-B1 | 1,2-annelated quinoline derivatives | JANSSEN PHARMACEUTICA N.V. (BE) | 2002-10-01 | — | — | US | claimed |
| EP-1140935-A2 | 1,2-ANNELATED QUINOLINE DERIVATIVES | JANSSEN PHARMACEUTICA N.V. (BE) | 2001-10-10 | — | — | EP | claimed |
| WO-2000039082-A2 | 1,2-ANNELATED QUINOLINE DERIVATIVES | JANSSEN PHARMACEUTICA N.V. (BE) | 2000-07-06 | — | — | WO | claimed |
| US-8557847-B2 | Synergistic modulation of FLT3 kinase using a FLT3 inhibitor and a farnesyl transferase inhibitor | JANSSEN PHARMACEUTICA, N.V. (BE) | 2013-10-15 | — | — | US | disclosed |
| EP-1815247-B1 | THERAPEUTIC USE OF FARNESYLTRANSFERASE INHIBITORS AND METHODS OF MONITORING THE EFFICACY THEREOF | JANSSEN PHARMACEUTICA NV (BE) | 2013-02-20 | — | — | EP | disclosed |
| US-20120196766-A1 | Therapeutic Use of Farnesyltransferase Inhibitors and Methods of Monitoring the Efficacy Thereof | FOURIE ANNE MADELEINE (US) | 2012-08-02 | — | — | US | disclosed |
| US-20120108634-A1 | FARNESYL PROTEIN TRANSFERASE INHIBITOR COMBINATIONS WITH ANTIESTROGEN AGENTS | END DAVID WILLIAM (US) | 2012-05-03 | — | — | US | disclosed |
| WO-2001064199-A2 | FARNESYL PROTEIN TRANSFERASE INHIBITOR COMBINATIONS WITH TAXANE COMPOUNDS | JANSSEN PHARMACEUTICA N.V. (BE) | 2001-09-07 | — | — | WO | disclosed |
| WO-2001064195-A2 | FARNESYL PROTEIN TRANSFERASE INHIBITOR COMBINATIONS WITH ANTI-TUMOR NUCLEOSIDE DERIVATIVES | JANSSEN PHARMACEUTICA N.V. (BE) | 2001-09-07 | — | — | WO | disclosed |
| WO-2001064218-A2 | FARNESYL PROTEIN TRANSFERASE INHIBITOR COMBINATIONS | JANSSEN PHARMACEUTICA N.V. (BE) | 2001-09-07 | — | — | WO | disclosed |
| WO-2001056552-A2 | FARNESYL PROTEIN TRANSFERASE INHIBITORS FOR TREATING BREAST CANCER | JANSSEN PHARMACEUTICA N.V. (BE) | 2001-08-09 | — | — | WO | disclosed |
| WO-2000039082-A2 | 1,2-ANNELATED QUINOLINE DERIVATIVES | JANSSEN PHARMACEUTICA N.V. (BE) | 2000-07-06 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120108634-A1 | FARNESYL PROTEIN TRANSFERASE INHIBITOR COMBINATIONS WITH ANTIESTROGEN AGENTS | FNTA, FNTB, PTAR1 | CYP19A1 31/4885FNTA 1/4885FNTB 2/4885 |
| US-20030119843-A1 | 1,2-annelated quinoline derivatives | NAT1, CYP7A1, CYP4A11 | CYP19A1 549/4885FNTA 19/4885FNTB 27/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.